Neurotrack competitors

Neurotrack's competitors include Transformative, NeuraLace Medical, EXACT Sciences and bioMerieux
Add company...
Neurotrack
Neurotrack's technology can predict the onset of Alzheimer's disease three to six years before symptoms occur.
Transformative
Transformative provides patent-pending algorithm to predict the onset of sudden cardiac arrest, allowing for advance warning, and preparation for intervention.
NeuraLace Medical
NeuraLace Medical has developed a proprietary neuromodulation platform for direct and selective stimulation of sensory nerve fibers to manage neuropathic pain.
EXACT Sciences
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
bioMerieux
bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety.
Founding Date
Founding Date
2012
Founding Date
2016
Founding Date
2016
Founding Date
1995
Founding Date
1963
Type
Type
Private
Type
Private
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Redwood City, US HQ
Locations
London, GB HQ
Locations
San Diego, US HQ
Locations
Madison, US HQ
Locations
Marcy-l'Étoile, FR HQ
Employees
Employees
249% increase
Employees
7
Employees
8
Employees
736
Employees
9,8065% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
6 b
Valuation ($)
9.3 b
Facebook likes
Facebook likes
3.4 k
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
5.4 k
Facebook likes
8.5 k
Twitter followers
Twitter followers
1.3 k
Twitter followers
N/A
Twitter followers
22
Twitter followers
2 k
Twitter followers
4.8 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$99.4m (FY, 2016)
Revenue (est.)
€2.1b (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$45.2m (FY, 2016)
Cost of goods
€1b (FY, 2016)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$54.2m (FY, 2016)
Gross profit
€1.1b (FY, 2016)
Net income
Net income
N/A
Net income
N/A
Net income
N/A
Net income
($167.2m) (FY, 2016)
Net income
€179.2m (FY, 2016)

Funding

Latest funding round
Latest funding round
$ 13.7m (5 months ago)
Latest funding round
$ 669.6k (11 months ago)
Latest funding round
$ 2m (over 1 year ago)
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 26.1m
Total funding raised
$ 669.6k
Total funding raised
$ 2m
Total funding raised
$ 8.2m
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Transformative
HQ
London, GB
Employees
7

Transformative provides patent-pending algorithm to predict the onset of sudden cardiac arrest, allowing for advance warning, and preparation for intervention.

View company
NeuraLace Medical
HQ
San Diego, US
Employees
8

NeuraLace Medical has developed a proprietary neuromodulation platform for direct and selective stimulation of sensory nerve fibers to manage neuropathic pain.

View company
EXACT Sciences
HQ
Madison, US
Employees
736

Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.

View company
bioMerieux
HQ
Marcy-l'Étoile, FR
Employees
9,806↑ 5% increase

bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety.

View company